Prime Highlight
- French medical-grade skincare brand Innerskin has secured $15 million from Iris Ventures to expand beyond France and enhance its advanced product line.
- The company plans rapid European growth, targeting 8–12 new clinics per year across the U.K., Ireland, Benelux, and major capitals.
Key Facts
- Founded by Chrystelle Eid, Innerskin currently operates 19 clinics in France and focuses on personalised, noninvasive treatments inspired by professional techniques.
- Innerskin’s products feature a proprietary complex called Mesotides and are sold through clinics, online, and select pop-ups, with no plans for mass retail.
Background
Innerskin, a French expert in medical-grade, noninvasive skin care, has raised $15 million in new funding from Iris Ventures. This investment helps the fast-growing brand expand outside France and improve its advanced skin care line.
Founded by Chrystelle Eid, Innerskin has rapidly built a network of 19 clinics across France. The brand focuses on preventive skin health, offering personalised treatments and a product line designed to mimic professional techniques such as microneedling. Eid said the new funding will help Innerskin open clinics across Europe, with sites already being explored in London neighbourhoods including Chelsea, Notting Hill, and Marylebone. The company aims to launch eight to 12 clinics each year in the U.K., the Republic of Ireland, Benelux, and other European capitals.
Eid described Iris Ventures’ backing as pivotal, highlighting the firm’s strong expertise in beauty and wellness. Iris joins existing investor Label Capital, adding its support to a portfolio that includes wellness and science-led consumer brands such as Healf, Superlativa, Biomel, and Olistic. Montse Suarez, founder and managing partner at Iris Ventures, praised Eid as an exceptional founder capable of scaling a sophisticated, high-quality aesthetic brand.
Innerskin’s approach centres on gentle, natural-looking results, which Eid calls the era of “undetectable beauty.” She said clients increasingly prefer to refine rather than transform their features. Her clinics aim to offer a warm, judgment-free experience, contrasting with traditional aesthetic settings that often push standardised beauty ideals.
The brand’s product line also reflects this philosophy. Built around a proprietary complex called Mesotides, the formulas use micro-encapsulation to improve skin absorption and deliver high performance. Products are sold in clinics, online, and through select pop-ups, with no plans for mass retail distribution.
The new funding positions Innerskin as a rising European leader in science-backed, personalised aesthetic care.
